Spring Creek Capital’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

Spring Creek Capital’s Portfolio BIOSW Stock Details BIOSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-250,000	Closed	-$55K	–	363
2022 Q1	$55K	Buy	+250,000	New	+$64.9K	﹤0.01%	547

Other funds holding BIOSW

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Spring Creek Capital's BIOSW Position: Q2 2022 in Review

Spring Creek Capital sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q2 2022, closing a stake of 250,000 shares — an estimated $55K sold.

Spring Creek Capital first reported a position in BIOSW in Q1 2022 and held it in 1 quarter. The position peaked at $55K in Q1 2022. 51 funds tracked by Wall St. Rank hold BIOSW as of Q2 2022.

Spring Creek Capital reported no remaining BioPlus Acquisition Corp. Warrants position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 250,000 BioPlus Acquisition Corp. Warrants shares in Q2 2022, an estimated $55K.
Spring Creek Capital first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 1 quarter.
Spring Creek Capital's BioPlus Acquisition Corp. Warrants position peaked at $55K in Q1 2022.
51 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.